✦ LIBER ✦

Amrubicin for treating elderly and poor-risk patients with small-cell lung cancer

✍ Scribed by Satoshi Igawa; Shinichiro Ryuge; Tomoya Fukui; Sakiko Otani; Yuka Kimura; Ken Katono; Akira Takakura; Masaru Kubota; Hisashi Mitsufuji; Masato Katagiri; Nobuo Yanase; Noriyuki Masuda

Publisher: Springer
Year: 2010
Tongue: English
Weight: 265 KB
Volume: 15
Category: Article
ISSN: 1341-9625
DOI: 10.1007/s10147-010-0085-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Therapy for poor-risk patients with smal

Therapy for poor-risk patients with small-cell lung cancer using bolus ifosfamide and oral etoposide

✍ H. Anderson; M. J. Lind; N. Thatcher; R. Swindell; A. Woodcock; K. B. Carroll 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 319 KB

Treatment of small-cell lung cancer in e

Treatment of small-cell lung cancer in elderly patients

✍ Athanasios G. Pallis; Frances A. Shepherd; Denis Lacombe; Cesare Gridelli 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

Cisplatin-based combination chemotherapy

Cisplatin-based combination chemotherapy for elderly patients with non-small-cell lung cancer

✍ Kaoru Kubota; Kiyoyuki Furuse; Masaaki Kawahara; Nagahisa Kodama; Mitsumasa Ogaw 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 146 KB

Clinical observation of docetaxel in tre

Clinical observation of docetaxel in treating advanced non-small cell lung cancer in the elderly patients

✍ Yongguang Cai; Xin Xie; Ming Li 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 230 KB

Phase I study of amrubicin and vinorelbi

Phase I study of amrubicin and vinorelbine in non-small cell lung cancer previously treated with platinum-based chemotherapy

✍ Satoshi Oizumi; Koichi Yamazaki; Hiroshi Yokouchi; Jun Konishi; Fumihiro Hommura 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 218 KB

Phase II trial of vindesine and VP16-213

Phase II trial of vindesine and VP16-213 in the palliation of poor-prognosis patients and elderly patients with small cell lung cancer

✍ Simon G. Allan; Anna Gregor; Michael A. Cornbleet; Robert C. F. Leonard; John F. 📂 Article 📅 1984 🏛 Springer 🌐 English ⚖ 320 KB

Forty-three previously untreated patients, all of whom had poor-prognosis small cell lung cancer and/or were greater than 65 years old, received treatment with vindesine and VP16-213. Thirteen patients had limited disease and 30 extensive disease. Response rates (CR + PR) of 86% (CR 29%) and 66% (CR